Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659618 · ClinicalTrials.gov registry record
Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
A clinical trial of Severe Persistent Asthma, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT02659618: Completed study of Severe Persistent Asthma, sponsored by Rush University Medical Center.
NCT02659618 is a study of Severe Persistent Asthma that has completed, run by Rush University Medical Center. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02659618, a study of Severe Persistent Asthma, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to identify a serum biomarker(s) that can detect increased levels of a population of CD15+ hypodense neutrophils termed low-density granulocytes (LDG) in the blood of patients with severe persistent asthma.
Conditions Studied
Study Locations (1)
Illinois
- University Consultants in Allergy/Immunology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-12-16 |
What the finished NCT02659618 record still lists
NCT02659618 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 1 condition, with Severe Persistent Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT02659618 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02659618 about?
NCT02659618 is a clinical study titled "Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma". The goal of this study is to identify a serum biomarker(s) that can detect increased levels of a population of CD15+ hypodense neutrophils termed low-density granulocytes (LDG) in the blood of patients with severe persistent asthma.
What is the current status of trial NCT02659618?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2016-04. Estimated completion is 2020-12-16.
What conditions does trial NCT02659618 study?
This clinical trial studies the following conditions: Severe Persistent Asthma.
Who is sponsoring clinical trial NCT02659618?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02659618 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia